Jack Bendheim Sells 7,040 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

February 24, 2026 by InsiderTrades.com

Key Points

CEO Jack Bendheim sold 7,040 shares on Feb. 20 at an average of $51.42 and now owns 22,600 shares; his insider sales since Jan. 23 total about 232,040 shares for roughly $11.33 million, representing substantial insider selling.
Phibro beat expectations for the quarter with $0.87 EPS (vs. $0.69 est.) and $373.9M revenue (vs. $355.6M est.), issued FY‑2026 EPS guidance of 2.93–3.10, and declared a $0.12 quarterly dividend (0.9% yield).
The stock trades around $51.52 with a market cap of $2.09B and a P/E of 22.9, is ~99.34% institutionally owned, and carries an average analyst rating of "Hold" with a $37.50 average target below the current price.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the firm's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80. Following the completion of the sale, the chief executive officer owned 22,600 shares in the company, valued at approximately $1,162,092. The trade was a 23.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08.
On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.
On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96.
On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.15, for a total value of $144,848.00.
On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total value of $400,600.20.
On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.
On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total value of $271,692.64.
On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $51.52 on Tuesday. The business has a 50 day moving average of $42.66 and a 200-day moving average of $40.31. The company has a market capitalization of $2.09 billion, a P/E ratio of 22.90, a P/E/G ratio of 0.81 and a beta of 0.80. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $56.30. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities research analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health's dividend payout ratio (DPR) is currently 21.33%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company's stock worth $57,519,000 after purchasing an additional 13,884 shares during the period. State Street Corp raised its holdings in shares of Phibro Animal Health by 5.4% during the fourth quarter. State Street Corp now owns 942,279 shares of the company's stock valued at $35,204,000 after purchasing an additional 48,243 shares during the period. Millennium Management LLC boosted its position in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company's stock worth $23,959,000 after purchasing an additional 626,492 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company's stock valued at $21,265,000 after buying an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Phibro Animal Health by 1.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company's stock valued at $18,394,000 after buying an additional 6,826 shares in the last quarter. 99.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Monday, February 9th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $37.50.

Get Our Latest Stock Report on PAHC

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.